Compare · CYT vs PFE
CYT vs PFE
Side-by-side comparison of Cyteir Therapeutics Inc. (CYT) and Pfizer Inc. (PFE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CYT and PFE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PFE is the larger of the two at $304.95B, about 1553.4x CYT ($196.3M).
- PFE has hit the wire 10 times in the past 4 weeks while CYT has been quiet.
- PFE has more recent analyst coverage (25 ratings vs 5 for CYT).
- Company
- Cyteir Therapeutics Inc.
- Pfizer Inc.
- Price
- -
- -
- Market cap
- $196.3M
- $304.95B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 10
- Recent ratings
- 5
- 25
Cyteir Therapeutics Inc.
Cyteir Therapeutics, Inc. operates as a clinical-stage oncology company that develops novel therapeutics based on the biology of DNA repair for the treatment of cancer and synthetic lethality therapeutics for autoimmune diseases. The company engages in manufacturing therapeutics that provide precision targeting of key DNA repair factors to induce diseased cells to self-destruct by DNA damage overload and uses an integrated drug development platform that modulates the imbalance between DNA damage and repair for the therapeutic effect to deliver a pipeline of small molecule therapeutics with a range of potential disease state applications. It provides CYT-0851, an oral small-molecule inhibitor of RAD51-mediated DNA repair. It focuses on providing treatments for a range of hematological malignancies, solid tumors, and chronic autoimmune disorders. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest CYT
- SEC Form 15-12G filed by Cyteir Therapeutics Inc.
- Leonard Braden Michael bought $503,238 worth of shares (170,589 units at $2.95) (SEC Form 4)
- SEC Form S-8 POS filed by Cyteir Therapeutics Inc.
- SEC Form S-8 POS filed by Cyteir Therapeutics Inc.
- SEC Form S-8 POS filed by Cyteir Therapeutics Inc.
- SEC Form AW filed by Cyteir Therapeutics Inc.
- SEC Form AW filed by Cyteir Therapeutics Inc.
- SEC Form AW filed by Cyteir Therapeutics Inc.
- Cyteir Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits
- SEC Form SC 13G/A filed by Cyteir Therapeutics Inc. (Amendment)
Latest PFE
- Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
- Pfizer Declares Second-Quarter 2026 Dividend
- Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
- U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- SEC Form 4 filed by Bourla Albert
- SEC Form 4 filed by Bourla Albert
- SEC Form 3 filed by new insider Hancock Dennis P
- Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
- Telix Strengthens Board with Additional Director Appointments
- AI-Enhanced Robotics in Pharma Manufacturing Signals Major Efficiency, Margin Expansion Opportunities